The Neurological Masquerade of Intravascular Lymphomatosis

Beristaín, Xabier; Azzarelli, Biagio

doi:10.1001/archneur.59.3.439

Cited by 108 publications

(93 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Immunohistochemically, they were positive for B-cell markers including CD 20 ( Fig. 1-C3 (3,4). The present case also showed that the symptoms closely resemble cerebral infarction, and she was medicated as having cerebral infarction.…”

Section: Intravascular Large B-cell Lymphoma (Ivl) Is a Rare Systemicsupporting

confidence: 59%

Intravascular Large B-cell Lymphoma Following a Relapsing Stroke with Temporary Fever: A Brain Biopsy Case

Imamura

Awaki²,

Aoyama³

et al. 2006

Intern. Med.

View full text Add to dashboard Cite

Intravascular large B-cell lymphoma (IVL) is a rare systemic disease that is characterized by massive intravascular growth of lymphoma cells with a predilection for the central nervous system. It is a subtype of diffuse large B-cell lymphoma as recognized by the World Health Organization classification (1). We report a case of IVL diagnosed by cerebral biopsy.A (Fig. 1-A). Gdenhanced T1-weighted images showed gyriform enhancement in the bilateral temporal lobes and nodular enhancement in the left parieto-occipital lobe (Fig. 1-B Fig. 1-C1, 2). Immunohistochemically, they were positive for B-cell markers including CD 20 (Fig. 1-C3) and CD 79a; they were negative for CD 3, CD 5, CD 10, CD 23 and CD 45 (3,4). The present case also showed that the symptoms closely resemble cerebral infarction, and she was medicated as having cerebral infarction. In our case, every time the patient came under stroke attack, she had a temporary fever that normalized as soon as her stroke symptoms improved. We suggest that relapsing stroke following a tem-

show abstract

Section: Intravascular Large B-cell Lymphoma (Ivl) Is a Rare Systemicsupporting

confidence: 59%

Intravascular Large B-cell Lymphoma Following a Relapsing Stroke with Temporary Fever: A Brain Biopsy Case

Imamura

Awaki²,

Aoyama³

et al. 2006

Intern. Med.

View full text Add to dashboard Cite

show abstract

“…Other important findings are bizarre neurological symptoms [9]. Most cases are diagnosed at autopsy because of misleading clinical features mimicking dementia, vasculitis, stroke, infection, or other neoplasm; in fact, in our case, all of these were considered as differential diagnoses.…”

Section: Discussionmentioning

confidence: 74%

Usefulness of FDG‐PET to diagnose intravascular lymphomatosis presenting as fever of unknown origin

et al. 2004

View full text Add to dashboard Cite

Intravascular lymphomatosis (IVL) is a rare systemic disease characterized by proliferation of lymphoid cells within the lumina of small arteries, veins, and capillaries. Diagnosis requires skin, liver, lung, bone marrow, renal, meningeal, or brain vessel biopsy but is often made only when the illness has progressed or post mortem because early involvement of organs was not evident. We report a case of IVL presenting as fever of unknown origin (FUO). In this case, gallium scintigraphy and computed tomography (CT) showed no evidence of malignancy, whereas 18 F-fluorodeoxyglucose positron emission tomography (FDG-PET) showed increased FDG uptake in the sternum, left and right vertebra, humerus, femur, and especially ilium. The diagnosis was made on iliac bone marrow biopsy examination. FDG-PET was useful for the detection of spread of disease in a patient with IVL suffering from FUO. Am.

show abstract

“…(12)(13)(14) Intravascular large B-cell lymphoma shows a high incidence of neurological symptoms, including sensory and motor deficits, palsy, altered consciousness, and seizures, associated with CNS involvement at diagnosis. (14)(15)(16)(17) Considering the clinically aggressive behavior accompanied by various CNS risk factors and high rate of CNS involvement at diagnosis, the risk of CNS relapse is considered extremely high. (3,4,10,15,18) Although previous reports have described some IVLBCL patients with CNS relapse and the resulting poor prognosis, (15,19,20) no large-scale study focusing on CNS involvement in IVLBCL patients has been reported.…”

mentioning

confidence: 99%

Central nervous system involvement in intravascular large B‐cell lymphoma: A retrospective analysis of 109 patients

et al. 2010

View full text Add to dashboard Cite

Intravascular large B-cell lymphoma (IVLBCL) is a rare disease entity with a high incidence of central nervous system (CNS) involvement at diagnosis. To evaluate CNS involvement, particularly recurrence including progression on therapy and relapse of IVLBCL, we retrospectively analyzed 109 patients with IVLBCL receiving chemotherapies with or without rituximab. In 82 patients (75%) without CNS involvement at initial diagnosis, risk of CNS recurrence at 3 years was 25% with a median follow-up in survivors of 39 months (range, 2-158 months). In 27 patients (25%) with CNS involvement at initial diagnosis, risk of CNS recurrence at 1 year was 25% with a median follow-up in survivors of 18 months (range, 10-77 months). Duration from diagnosis to CNS recurrence tended to be short in patients with CNS involvement at diagnosis. No significant difference in risk of CNS recurrence was found between patients receiving chemotherapies with or without rituximab. On multivariate analysis skin involvement at initial diagnosis was identified as a predictive factor for CNS recurrence in patients without CNS involvement at diagnosis (hazard ratio, 5.27; 95% confidence interval, 1.59-17.4; P = 0.007). Survival rate after CNS recurrence at 2 years was 12% in patients without CNS involvement at diagnosis. Central nervous system recurrence is a serious complication in IV-LBCL patients and optimal strategies for CNS involvement should be established to obtain further improvements to clinical outcomes in the rituximab era. (Cancer Sci 2010; 101: 1480-1486 C entral nervous system (CNS) involvement, particularly recurrence including progression during therapy or relapse after completion of chemotherapy, represents a serious and usually fatal complication of aggressive lymphoma.(1-5) Risk of CNS recurrence differs according to the histological type of lymphoma, occurring in 30-50% of cases involving Burkitt lymphoma (BL) and acute lymphoblastic leukemia ⁄ lymphoma (ALL ⁄ LBL), (6) and in around 5% of cases with aggressive nonHodgkin lymphoma (excluding BL and LBL) without CNS prophylaxis.(7) In BL and LBL, prophylaxis and early diagnosis of CNS involvement have led to major decreases in the risk of CNS relapse. (8,9) Adopting an initial treatment strategy including CNS prophylaxis is thus important, given the risk of CNS relapse.In previous reports, risk of CNS relapse in diffuse large B-cell lymphoma (DLBCL) has been approximately 5% and various CNS risk factors have been described, including advanced stage, increased international prognostic index (IPI), elevated serum lactate dehydrogenase (LDH), >1 extranodal site, and retroperitoneal disease. (3,4,10) Intravascular large B-cell lymphoma (IVLBCL) has recently been classified as a distinct rare disease entity according to the current World Health Organization (WHO) classification. (11) Intravascular large B-cell lymphoma is a rapidly progressive and disseminated, often fatal, aggressive lymphoma, characterized by selective growth of lymphoma cells only in the lumina of small vessels in ...

show abstract

The Neurological Masquerade of Intravascular Lymphomatosis

Cited by 108 publications

References 24 publications

Intravascular Large B-cell Lymphoma Following a Relapsing Stroke with Temporary Fever: A Brain Biopsy Case

Intravascular Large B-cell Lymphoma Following a Relapsing Stroke with Temporary Fever: A Brain Biopsy Case

Usefulness of FDG‐PET to diagnose intravascular lymphomatosis presenting as fever of unknown origin

Central nervous system involvement in intravascular large B‐cell lymphoma: A retrospective analysis of 109 patients

Contact Info

Product

Resources

About